biotech

More Health Care Catalysts to Watch For by the End of February

Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining ...
Read Full Story »

Moleculin Biotech Explodes on Breakthrough Cancer Treatment

Moleculin Biotech Inc. (NASDAQ: MBRX) watched its shares climb on Thursday after the company announced a new breakthrough for cancer treatment. While this is broad and could hold multiple applications, ...
Read Full Story »

Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of complicated ...
Read Full Story »

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

While the market has bounced back smartly over the past few sessions, one thing is for sure: the baby was tossed out with the proverbial bathwater in many sectors. Nowhere ...
Read Full Story »

Why Catabasis Is Tuesday’s Biggest Winner

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy (DMD) study with edasalonexent. Overall the trial showed ...
Read Full Story »

BioXel Gears Up for IPO

BioXel Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the ...
Read Full Story »

Is This the End of Axovant?

Axovant Sciences Ltd. (NASDAQ: AXON) saw its shares take a big step back to start out the week after the company announced that there would be some changes at the ...
Read Full Story »

Major Biotechs See Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Theravance Biopharma Shares Are Soaring

Shares of Theravance Biopharma Inc. (NASDAQ: TBPH) saw a solid gain on Wednesday after the company announced a global collaboration with Johnson & Johnson (NYSE: JNJ) subsidiary, Janssen Biotech. The ...
Read Full Story »

Major Biopharma Catalysts on February’s FDA Calendar

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to ...
Read Full Story »

Can Zynerba Pharma Shares Really Still Double in These High Times?

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has multiple issues that may be working in its favor. The small-cap stock is often lumped in with legalized marijuana and medical marijuana stocks, as ...
Read Full Story »

6 Speculative Biotech Stocks With 50% to 250% Potential Upside

It's no secret that one of the strongest raging bull markets of our lifetime is taking place. At the start of 2018, the bull market was almost nine years old. Many ...
Read Full Story »

Top Stocks to Look For in February’s FDA Calendar

Companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. ...
Read Full Story »

Short Sellers Raise the Stakes in Major Biotechs

The short interest data are out for the most recent settlement date, January 12. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Analysts Are Slashing Their Targets for Puma Biotechnology

Puma Biotechnology Inc. (NASDAQ: PBYI) saw its shares take a dive on Wednesday following regulatory events in Europe. Specifically, the Committee for Medicinal Products for Human Use (CHMP) of the ...
Read Full Story »